2020, December, London
Leeaf Established Its UK Subsidiary
LONDON (Dec 2020): Leeaf established its UK subsidiary to serve UK patients and clinics with an AI-powered IVF platform. “Our market tests last year indicated that UK patients are not only in need of but also actively searching for novel approaches to solving their infertility challenges. Strong competition among UK IVF centres seems to provide a vibrant and open environment for progressive, evidence-based approaches and conducting high-quality research in the field of IVF. These two reasons lead us to prioritize the UK market, and we are humbled and excited at the same time about this strategic move,” said Jan Choma, Leeaf’s founder and CEO.
2020, December, Prague
Leaf Secures a $750,000 Seed Investment To Fund The Development Of The IVF Platform Powered By AI.
PRAGUE (Dec 2020): Leeaf announced a $750,000 investment from a group of private investors to fund the IVF platform's development powered by AI.
"We are excited to be able to move forward with our IVF platform development," said Jan Choma, Founder and CEO of Leeaf. "This investment will help accelerate the process of bringing individualized, AI-supported fertility treatments to women who are struggling with fertility issues."
The Leeaf Fertility Platform will combine the power of data-driven medicine with the ease of use of today’s mobile applications to provide individualized treatment options and conception plans to the community of women looking to take control of their fertility. The iOS and Android mobile application will provide powerful real-time insights for women, clinicians, and fertility researchers to improve outcomes and build healthy families.
As the use of ever more powerful sensors provides health data at a scale that was inconceivable just a short time ago, so too are technologies such as machine learning and AI showing us the way to understand and utilise this data to produce more predictive, more personalised and simply more effective treatments. Leeaf is the trusted bridge between the patients, doctor and data.
"It is great to have a partner who understands the value of Leeaf's Fertility platform and the good this work will do for women and families across Europe and around the world," added Choma.
2019, November, Lisbon
Leeaf’s CEO and Founder Discussed the Role of AI in Improving IVF Processes and Outcomes with Participants of Fertility & AI Forum.
LISBON (Nov, 2019): Jan Choma discussed with participants of the Fertility and AI Forum in Lisbon our vision of AI's role in improving IVF processes and treatment outcomes. Choma’s view of the IVF future covered recent advances in fertility that employ Artificial Intelligence (AI) across almost all steps of IVF treatment – starting with improving egg quality, followed by more effective and less risky stimulation protocol including optimisation of key timing decisions at the end of stimulation, down to embryo evaluation.
“These early advances in reproductive therapies using AI open up huge possibilities for women who have challenges with having a baby,” said Choma. “Not only will this make fertility treatments more accessible and affordable, but it will also help improve outcomes, resulting in more happy families.”
The First Fertility and AI Forum bring together medical professionals, researchers, and solution providers worldwide with some of the biggest players in the field, including pharmaceutical companies, research universities, medical equipment manufacturers, technology companies, and more.
“At the end of the day, the goal is to make life better for the one in every six families who have trouble with fertility, said Choma. “Fertility & AI Forum proved our vision - four globally well-known and respected IVF clinics have developed pilot projects successfully applying AI to improve IVF results. It’s a long journey ahead of us, and I’m honoured to be a part of that.”
2017, September, Prague
Leeaf’s CEO and Founder Presented the First Cognitive System for Human Embryo Evaluation at FuturePort
PRAGUE (Sept, 2017): Jan Choma presented the first Cognitive System for Human Embryo Evaluation to the FuturePort Conference attendees in Prague. Choma explained how machine learning, a branch of Artificial Intelligence (AI), improves embryo selection during In-Vitro Fertilization procedures.
“I was pleased to be able to share the latest advancements in AI with the FuturePort Conference,” said Choma. “This pilot project proved that AI can help physicians and clinics save time and money while improving outcomes for women.”
Artificial Intelligence (AI) can evaluate the development of embryos. This is important in assisted reproduction because not all embryos prove viable enough to lead to a healthy baby's birth.
"Every sixth couple in the developed world today suffers from infertility," said Choma.
This AI system examines up to 400 markers for each embryo in a fraction of the time it takes a human to do the same work. The work that might normally take one embryologist one to two hours per day can now be done with neural network-based AI in 45 seconds.
"The accuracy is 91 to 99 per cent, which is higher than most embryology experts," said Choma. “And while it is still early days yet for fully implementing this AI globally, it won’t be long until we see new technology like this making a difference and helping women and their partners have successful pregnancies all around the world.”
GROW YOUR CLINIC WITH LEEAF
If you are interested in becoming part of a rapidly evolving, therapeutic, transformative and life changing ecosystem, we invite you to become part of the conversation.